CALCIUM GLUCONATE injection, solution

Calcium Gluconate by

Drug Labeling and Warnings

Calcium Gluconate by is a Prescription medication manufactured, distributed, or labeled by Henry Schein, Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • These highlights do not include all the information needed to use CALCIUM GLUCONATE INJECTION safely and effectively. See full prescribing information for CALCIUM GLUCONATE INJECTION.CALCIUM GLUCONATE injection, for intravenous useInitial U.S. Approval: 1941

  • 1 INDICATIONS AND USAGE

    Calcium Gluconate Injection is indicationd for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia.

    Limitations of Use

    The safety of Calcium Gluconate Injection for long term use has not been established.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Important Administration Instructions

    • Calcium Gluconate Injection contains 100 mg of calcium gluconate per mL which contains 9.3 mg (i.e., 0.465 mEq) of elemental calcium.
    • Dilute Calcium Gluconate Injection prior to use in 5% dextrose or normal saline and assess for potential drug or IV fluid incompatibilities [see Dosage and Administration (2.5)].
    • Inspect Calcium Gluconate Injection visually prior to administration. The solution should appear clear and colorless to slightly yellow. Do not administer if there is particulate matter or discoloration.
    • Use the diluted solution immediately after preparation.
    • Administer Calcium Gluconate Injection intravenously via a secure intravenous line to avoid calcinosis cutis and tissue necrosis [see Warnings and Precautions(5.3)].
    • Administer Calcium Gluconate Injection by bolus administration nor continuous infusion:

    For bolus intravenous administration:

    • Dilute the dose [see Dosage and Administration (2.2)] of Calcium Gluconate Injection in 5% dextrose or normal saline to a concentration 10-50 mg/mL prior to administration. Administer the dose slowly and DO NOT exceed an infustion rate of 200 mg/minute in adults or 100 mg/minute in pediatric patients, including neonates. Monitor patients, vitals and electrocardiograph (ECG) during administration [see Warnings and Precautions (5.4)].

    For continuous intravenous infusion:

    • Dilute Calcium Gluconate Injection in 5% dextrose or normal saline to a concentration of 5.8-10 mg/mL prior to administration. Administer at the rate recommended in Table 1 [see Dosage and Administration (2.2)] and monitor patients, vitals, calcium and ECG during the infusion [see Warnings and Precautions (5.4)].
    • Calcium Gluconate Injection is supplied in single-dose vials and pharmacy bulk packages [see Dosage and Administration (2.6)].

    2.2 Recommended Dosage

    Individualize the dose of Calcium Gluconate Injection within the recommended range depending on the severity of symptoms of hypocalcemia, the serum clacium level, and the acuity of onset of hypocalcemia.

    Table 1 provides dosing recommendations for Calcium Gluconate Injection in mg of calcium gluconate for neonates, pediatric and adult patients.

    Image1.jpg

    2.3 Serum Calcium Monitoring

    Measure serum calcium every 4 to 6 hours during intermittent infusions with Calcium Gluconate Injection and measure serum calcium every 1 to 4 hours during continuous infusion.

    2.4 Dosage in Renal Impairment

    For patients with renal impairment, initiate Calcium Gluconate Injection at the lowest dose of the recommended dose ranges for all age groups and monitor serum calcium levels every 4 hours.

    2.5 Drug Incompatibilities

    • Do not mix Calcium Gluconate Injection with ceftriaxone. Concurrent use of intravenous ceftriaxone and Calcium Gluconate Injection can lead to the formation of ceftriaxone-calcium precipitates. Concomitant use of ceftriaxone and intravenous calcium-containing products is contraindicated in neonates (28 days of age or younger) see Contraindications (4)]. In patients older than 28 days of age, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. Ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions via a Y-site in any age group [see Warnings and Precautions (5.2), Drug Interactions (7.3)].
    • Do not mix Calcium Gluconate Injection with fluids containing bicarbonate or phosphate. Calcium Gluconate Injection is not physically compatible with fluids containing phosphate or bicarbonate. Precipitation may result if mixed.
    • Do not mix Calcium Gluconate Injection with minocycline injection. Calcium complexes minocycline rendering it inactive.

    2.6 Preparation of Pharmacy Bulk Package

    The pharmacy bulk package (PBP) of Calcium Gluconate Injection is intended for dispensing of single doses to multiple patients in a pharmacy admixture program. Penetrate the container closure only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. Use the PBP only in a suitable ISO Class 5 work area such as a laminar flow hood (or an equivalent clean air compounding area). Complete dispensing from the pharmacy bulk vial within 4 hours after the container closure is penetrated. Each dose dispensed from the Pharmacy Bulk Package vial must be used immediately.

  • 3 DOSAGE FORMS AND STRENGTHS

    Calcium Gluconate Injection, USP is a clear, colorless to slightly yellow, solution avaialbe in the following:

    • Single-dose vial: 1,000 mg per 10 mL (100 mg per mL)
    • Single-dose vial: 5,000 mg per 50 mL (100 mg per mL)
    • Pharmacy bulk package: 10,000 mg per 10 mL (100 mg per mL)

    Each mL of Calcium Gluconate Injection, USP contains 9.3 mg (0.465 mEq) of elemental calcium.

  • 4 CONTRAINDICATIONS

    Calcium Gluconate Injection is contraindicated in:

    • Hypercalcemia
    • Neonates (28 days of age or younger) receiving ceftriaxone [see Warnings and Precautions (5.2)]
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Arrhythmias with Concomitant Cardiac Glycoside Use

    Cardiac arrhythmias may occur if calcium and cardiac glycosides are administered together. Hyperclacemia increases the risk of digoxin toxicity. Adminsitration of Calcium Gluconate Injection should be avoided in patients receiving cardiac glycosides. If concomitant therapy is necessary, Calcium Gluconate Injection should be given slowly in small amounts and with close ECG monitoring [see Drug Interactions (7.1)].

    5.2 End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates

    Concomitant use of ceftriaxone and Calcium Gluconate Injection is contraindicated in neonates (28 days of ane or younger) due to cases of fatal outcomes in neonates in which a crystalline material was observed in the lungs and kidneys at autopsy after ceftriaxone and calcium were administrated simultaneously through the same intravenous line. Concomitant administration can lead to the formation of ceftriaxone-calcium precipitates that may act as emboli, resulting in vascular spasm or infarction [see Contraindications (4)].

    In patients older than 28 days of age, ceftriaxone and Calcium Gluconate Injection may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. Do not administer Ceftriaxone simultaneously with Calcium Gluconate Injection via a Y-site in any age group.

    5.3 Tissue Necrosis and Calcinosis

    Intravenous administration of Calcium Gluconate Injection and local trauma may result in calcinosis cutis due to transient increase in local calcium concentration. Calcinosis cutis can occur with or without extravasation of Calcium Gluconate Injection, is characterized by abnormal dermal deposits of calcium salts, and clinically manifests as papules, plaques, or nodules that may be associated with erythema, sweling, or induration. Tissue necrosis, ulceration, and secondary infection are the most serious complications.

    If extravasation occurs or clinical manifestations of calcinosis cutis are noted, immediately discontinue intravenous administration at that site and treat as needed.

    5.4 Hypotension, Bradycardia, and Cardiac Arrhythmias with Rapid Administration

    Rapid injection of Calcium Gluconate Injection may cause vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmias, syncope and cardiac arrest. To avoid adverse reactions that may follow rapid intravenous administration, Calcium Gluconate Injection should be diluted with 5% dextrose or normal saline and infused slowly. If rapid intravenous bolus of Calcium Gluconate Injection is required, the rate of intravenous administration should not exceed 200 mg/minute in adults and 100 mg/minute in pediatric patients and ECG monitoring during administration is recommended [see Dosage and Administration(2.1)].

    5.5 Aluminum Toxicity

    Calcium Gluconate Injection contains contains aluminum, up to 512 mcg per liter, that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 mcg/kg/day to 5 mcg/kg/day accumulate aluminum levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

  • 6 ADVERSE REACTIONS

    The following serious adverse reactions are also described elsewhere in the labeling:

    • Arrhythmias with Concomitant Cardiac Glycoside Use [see Warnings and Precautions (5.1)]
    • End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates [see Warnings and Precautions (5.2)]
    • Tissue Necrosis and Calcinosis [see Warnings and Precautions (5.3)]
    • Hypotension, Bradycardia, and Cardiac Arrhythmias [see Warnings and Precautions (5.4)]
    • Aluminum toxicity [see Warnings and precautions (5.5)]

    The following adverse reactions associated with the use of calcium gluconate were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

    Cardiovascular: Vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmia, syncope, cardiac arrest

    Administration site reactions:Local soft tissue inflammation, local necrosis, calcinosis cutis and calcification due to extravasation

  • 7 DRUG INTERACTIONS

    7.1 Cardiac Glycosides

    Hypercalcemia increases the risk of digoxin toxicity, while digoxin may be therapeutically ineffective in the presence of hypocalcemia. Synergistic arrhythmias may occur if calcium and cardiac glycosides are administered together. Avoid administration of Calcium Gluconate Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate injection slowly in small amounts and monitor ECG closely during administration.

    7.2 Calcium Channel Blockers

    Administration of calcium may reduce the response to calcium channel blockers.

    7.3 Drugs that may cause Hypercalcemia

    Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. Monitor plasma calcium concentrations in patients taking these drugs concurrently.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk summary

    Limited available data with Calcium Gluconate Injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. There are risks to the mother and the fetus associated with hypocalcemia in pregnancy [see Clinical Considerations].

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

    Clinical Considerations

    Disease-associated maternal risk

    Maternal hypocalcemia can result in an increased rate of spontaneous abortion, premature and dysfunctional labor, and possibly preeclampsia.

    Fetal/Neonatal adverse reactions

    Infants born to mothers with hypocalcemia can have associated fetal and neonatal hyperparathyroidism, which in turn can cause fetal and neonatal skeletal demineralization, subperiosteal bone resorption, osteitis fibrosa cystica and neonatal seizures. Infants born to mothers with hypocalcemia should be carefully monitored for signs of hypocalcemia or hypercalcemia, including neuromuscular irritability, apnea, cyanosis and cardiac rhythm disorders.

    8.2 Lactation

    Risk summary

    Calcium is present in human milk as a natural component of human milk. It is not known whether intravenous administration of Calcium Gluconate Injection can alter calcium concentration in human milk. There are no data on the effects of Calcium Gluconate Injection on the breastfed infant, or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Calcium Gluconate Injection and any potential adverse effects on the breastfed child from Calcium Gluconate Injection or from the underlying maternal condition.

    8.4 Pediatric Use

    The safety and effectiveness of Calcium Gluconate Injection have been established in pediatric patients for the treatment of acute, symptomatic hypocalcemia.

    Pediatric approval for Calcium Gluconate Injection, including doses, is not based on adequate and well-controlled clinical studies. Safety and dosing recommendations in pediatric patients are based on published literature and clinical experience [see Dosage and Administration (2.2).

    Concomitant use of ceftriaxone and Calcium Gluconate Injection is contraindicated in neonates (28 days of age or younger) due to reports of fatal outcomes associated with the presence of lung and kidney ceftriaxone-calcium precitpiates. In patients older than 28 days of age, ceftriaxone and Calcium Gluconate Injection may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid [see Contraindications (4) and Warnings and Precautions (5.2)]. This product contains up to512 mcg/mL aluminum which may be toxic, particularly for premature neonates due to immature renal function. Parenteral administration of aluminum greater than 4 to 5 mcg/kg/day is associated with central nervous system and bone toxicity [see Warnings and Precautions (5.5)].

    8.5 Geriatric Use

    In general dose selection for an elderly patient should start at the lowest dose of the recommended dose range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or oether drug therapy.

    8.6 Renal Impairment

    For patients with renal impairment, initiate Calcium Gluconate Injection at the loest dose of the recommended dose ranges across all age groups. Monitor serum calcium levels every 4 hours [see Dosage and Administration (2.4)].

    8.7 Hepatic Impairment

    Hepatic function does not impact the availability of ionized calcium after clacium gluconate intravenous administration. Dose adjustment in hepatically imapired patients may not be necessary.

  • 10 OVERDOSAGE

    Overdosage of Calcium Gluconate Injection may result in hypercalcemia. Symptoms of hypercalcemia typically develop when the total serum calcium concentration is ≥12 mg/dL. Neurologic symptoms include depression, weakness, fatigue, and confusion at lower levels, with patients experiencing hallucinations, disorientation, hypotonicity, seizures, and coma. Effects on the kidney include diminished ability to concentrate urine and diuresis.

    If overdose of Calcium Gluconate Injection occurs immediately discontinue administration and provide supportive treatments to restore intravascular volume as well as promote calcium excretion in the urine if necessary.

  • 11 DESCRIPTION

    Calcium Gluconate Injection, USP is a sterile, preservative-free, nonpyrogenic, supersaturated solution of calcium gluconate, a form of calcium, for intravenous use.

    Calcium Gluconate is calcium D-gluconate (1:2) monohydrate. The structural formula is:

    Formula1.jpg

    Molecular formula: C12H22CaO14 H2O
    Molecular weight: 448.39
    Solubility in water: 3.5 g/100 mL at 25°C

    Calcium Gluconate Injection, USP is available as 1,000 mg per 10 mL (100 mg per mL) or 5,000 mg per 50 mL (100 mg per mL) in a single-dose vial, or 10,000 mg per 100 mL (100 mg per mL) in a pharmacy bulk package.

    Each mL of Calcium Gluconate Injection, USP contains 100 mg of calcium gluconate (equivalent to 94 mg of calcium gluconate and 4.5 mg of calcium saccharate tetrahydrate), hydrochloric acid and/or sodium hydroxide for pH adjustment (6.0 to 8.2) and sterile water for injection, q.s. It contains no antimicrobial agent.

    Each mL of Calcium Gluconate Injection, USP contains 9.3 mg (0.465 mEq) of elemental calcium.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Intravenous administration of calcium gluconate increases serum ionized calcium level. Calcium gluconate dissociates into ionized calcium in plasma. Ionized calcium and gluconate are normal constituents of body fluids.

    12.3 Pharmacokinetics

    Absorption

    Calcium Gluconate Injection is 100% bioavailable following intravenous injection.

    Metabolism

    Calcium iteself does not undergo direct metabolism. The release of ionized calcium from intravenous administration of calcium gluconate is direct and does not seem to be affected by the first pass through the liver.

    Distribution

    Calcium in the body is distributed mainly in skeleton (99%). Only 1% of the total body calcium is distributed within the extracellular fluids and soft tissues. About 50% of total serum calcium is in the ionized form and represents the biologically active part. 8% to 10% serum calcium is bound to organic and inorganic acid and approximately 40% is protein-bound (primarily to ablumin).

    Elimination

    Studies have shown a relationship between urinary calcium excretion and the intravenous administration of calcium gluconate, with a significant increase in urinary calcium excretion observed after the intravenous administration of calcium gluconate.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of Calcium Gluconate Injection. Calcium gluconate was not mutagenic with or without metabolic activation in the Ames test with Salmonella typhimurium (strains TA-1535, TA-1537, and TA-1538) or Saccharomyces cerevisiae (Strain D4). Fertility studies in animals have not been conducted with calcium gluconate administered by the intravenous route.

  • HOW SUPPLIED/STORAGE AND HANDLING

    Calcium Gluconate Injection, USP is a clear, colorless to slightly yellow solution supplied as follows:

    Image2.jpg

    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze.

    Preservative Free. Discard any unused portion in the single-dose vial immediately or the Pharmacy Bulk Package vial within 4 hours after initial closure puncture.

    Each dose dispensed from the Pharmacy Bulk Package vial must be used immediately.

    The diluted solution must be used immediately.

    NOTE: Supersaturated solutions are prone to precipitation. The precipitate, if present, may be dissolved by warming the vial to 60° to 80°C, with occasional agitation, until the solution becomes clear. Shake vigorously. Allow to cool to room temperature before dispensing. Use injection only if clear immediately prior to use.

    Product repackaged by: Henry Schein, Inc., Bastian, VA 24314 
    From Original Manufacturer/Distributor's NDC and Unit of SaleTo Henry Schein Repackaged Product NDC and Unit of SaleTotal Strength/Total Volume (Concentration) per unit 
    NDC: 63323-360-19
    25 x 10 mL single dose vials    		NDC: 0404-9831-10
    1 10 mL single dose vial in a bag
    (Vial bears NDC: 63323-360-01)    		1,000 mg calcium gluconate per 10 mL
    (100 mg per mL)
    NDC: 63323-360-59
    25 x 50 mL single dose vials    		NDC: 0404-9831-50
    1 50 mL single dose vial in a bag
    (Vial bears NDC: 63323-360-03)    		5,000 mg calcium gluconate per 50 mL
    (100 mg per mL)

  • PATIENT COUNSELING INFORMATION

    • Advise the patient that the risks associated with infusion including local tissue inflammation, local necrosis and calcinosis. [see Warnings and Precautions ( 5.3)] .
    FRESENIUS KABI

    Lake Zurich, IL 60047

    www.fresenius-kabi.com/us

    451463C

    Revised: June 2023

  • SAMPLE PACKAGE LABEL

    Label1.jpgLabel2.jpg

  • INGREDIENTS AND APPEARANCE
    CALCIUM GLUCONATE 
    calcium gluconate injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0404-9831(NDC:63323-360)
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CALCIUM GLUCONATE MONOHYDRATE (UNII: CZN0MI5R31) (CALCIUM CATION - UNII:2M83C4R6ZB) CALCIUM GLUCONATE MONOHYDRATE98 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    CALCIUM SACCHARATE (UNII: 6AP9J91K4V)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0404-9831-501 in 1 BAG01/09/2022
    150 mL in 1 VIAL, PLASTIC; Type 0: Not a Combination Product
    2NDC: 0404-9831-101 in 1 BAG01/09/2022
    210 mL in 1 VIAL, PLASTIC; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20841801/09/2022
    Labeler - Henry Schein, Inc. (012430880)
    Establishment
    NameAddressID/FEIBusiness Operations
    Henry Schein, Inc.830995189relabel(0404-9831)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.